var data={"title":"Vitamin D2 (ergocalciferol): Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Vitamin D2 (ergocalciferol): Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6121?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=vitamin-d2-ergocalciferol-patient-drug-information\" class=\"drug drug_patient\">see &quot;Vitamin D2 (ergocalciferol): Patient drug information&quot;</a> and <a href=\"topic.htm?path=vitamin-d2-ergocalciferol-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Vitamin D2 (ergocalciferol): Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F166127\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Calcidol [OTC];</li>\n      <li>Calciferol [OTC];</li>\n      <li>Drisdol [DSC];</li>\n      <li>Drisdol [OTC] [DSC]</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F166128\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>D-Forte;</li>\n      <li>Erdol</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F166157\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Vitamin D Analog</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F166131\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> 1 mcg = 40 units</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Osteoporosis prevention (off-label use):</b> Adults &ge;50 years: 800 to 1000 units/day (NOF guidelines, 2014)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Vitamin D deficiency treatment (off-label dose):</b> (Holick, 2011): Oral: 6000 units daily or 50,000 units once weekly for at least 8 weeks to achieve a 25(OH)D level &gt;30 ng/mL; then maintenance dose of 1500 to 2000 units daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Special populations (obese patients, patients on medications known to affect vitamin D metabolism, patients with malabsorption syndromes): 6000 to 10,000 units daily to achieve a 25(OH)D level &gt;30 ng/mL; then maintenance dose of 3000 to 6000 units daily</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Vitamin D deficiency/insufficiency</b> in patients with CKD stages 3 to 4 (K/DOQI, 2003): <b>Note:</b> Dose is based on 25-hydroxyvitamin D serum level (25[OH]D): Oral (treatment duration should be a total of 6 months):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Serum 25(OH)D &lt;5 ng/mL:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">50,000 units/week for 12 weeks, then 50,000 units/month</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Serum 25(OH)D 5 to 15 ng/mL:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">50,000 units/week for 4 weeks, then 50,000 units/month</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Serum 25(OH)D 16 to 30 ng/mL:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">50,000 units/month</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hypoparathyroidism:</b> Oral: 1.25 to 5 mg/day (50,000 to 200,000 units) with calcium supplements</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Vitamin D</b>\n      <b>\n        <i>-resistant </i></b> <b>rickets:</b> Oral: 12,000 to 500,000 units/day</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F166147\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=vitamin-d2-ergocalciferol-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Vitamin D2 (ergocalciferol): Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> 1 mcg = 40 units</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dietary Reference Intake for Vitamin D:</b> Oral</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Breast-fed (fully or partially) Infants:</i> Oral: 10 mcg/day (400 units/day) beginning in the first few days of life; continue supplementation until infant is weaned to &ge;1 L/day or 1 quart/day of vitamin D-fortified formula or whole milk (after 12 months of age) (Wagner, 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Nonbreast-fed Infants, Older Children ingesting &lt;1,000 mL of vitamin D-fortified formula or milk:</i> Oral: 10 mcg/day (400 units/day) (Wagner, 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Children with increased risk of vitamin D deficiency (chronic fat malabsorption, maintained on chronic antiseizure medications):</i> Oral: Higher doses may be required; use laboratory testing [25 (OH)D, PTH, bone mineral status] to evaluate (Wagner, 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Vitamin D deficiency treatment (off-label use)</b> (Holick, 2011):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants 0 to 1 year: 2,000 units daily or 50,000 units once weekly for 6 weeks to achieve a 25(OH)D level &gt;30 ng/mL; then maintenance dose of 400 to 1,000 units daily.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children and Adolescents 1 to 18 years: 2,000 units daily or 50,000 units once weekly for at least 6 weeks to achieve a 25(OH)D level &gt;30 ng/mL; then maintenance dose of 600 to 1,000 units daily.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Vitamin D deficiency/insufficiency</b> in patients with CKD stages 3 to 4 (K/DOQI, 2005): <b>Note:</b> Dose is based on 25-hydroxyvitamin D serum level (25[OH]D): Oral (treatment duration should be a total of 3 months):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Serum 25(OH)D &lt;5 ng/mL:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">8,000 units/day for 4 weeks, then 4,000 units/day for 2 months <b>or</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">50,000 units/week for 4 weeks, then 50,000 units twice a month for 2 months</p>\n    <p style=\"text-indent:0em;margin-left:2em;\">Serum 25(OH)D 5 to 15 ng/mL:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">4,000 units/day <b>or</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">50,000 units every other week</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Serum 25(OH)D 16 to 30 ng/mL:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">2,000 units/day <b>or</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">50,000 units every 4 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hypoparathyroidism:</b> Oral: 1.25 to 5 mg/day (50,000 to 200,000 units) and calcium supplements</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Vitamin D</b>\n      <b>\n        <i>-resistant </i></b> <b>rickets:</b> Oral: 12,000 to 500,000 units/day</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15822439\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15822440\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F166109\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Drisdol: 50,000 units [DSC] [contains brilliant blue fcf (fd&amp;c blue #1), soybean oil, tartrazine (fd&amp;c yellow #5)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 50,000 units</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Calcidol: 8000 units/mL (60 mL) [contains propylene glycol]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Calciferol: 8000 units/mL (60 mL) [contains propylene glycol]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Drisdol: 8000 units/mL (60 mL [DSC]) [contains propylene glycol]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 8000 units/mL (60 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 400 units, 2000 units</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F166094\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25571070\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Liquid vitamin D preparations have the potential for dosing errors when administered to infants. The FDA recommends using droppers that deliver no more than 400 units per dose for products intended for infants.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F166112\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dietary supplement:</b> For use as a vitamin D supplement.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Familial hypophosphatemia:</b> Treatment of familial hypophosphatemia.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hypoparathyroidism:</b> Treatment of hypoparathyroidism.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Rickets:</b> Treatment of refractory rickets, also known as vitamin D-resistant rickets.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25575027\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Prevention and treatment of vitamin D deficiency in patients with chronic kidney disease (CKD) (adults); Prevention and treatment of vitamin D deficiency in patients with chronic kidney disease (CKD) (children); Osteoporosis prevention</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F166164\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Calciferol may be confused with calcifediol, calcitriol</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Drisdol may be confused with Drysol</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Ergocalciferol may be confused with alfacalcidol, cholecalciferol</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Administration issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Liquid vitamin D preparations have the potential for dosing errors when administered to infants. Droppers should be clearly marked to easily provide 400 units. For products intended for infants, the FDA recommends that accompanying droppers deliver no more than 400 units per dose.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F166101\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Frequency not defined: Endocrine &amp; metabolic: Hypervitaminosis D</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F166116\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypercalcemia; malabsorption syndrome; abnormal sensitivity to the toxic effects of vitamin D; hypervitaminosis D</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note:</b> Although the manufacturer&rsquo;s labeling lists use in malabsorption syndrome as contraindicated, when dosed appropriately, ergocalciferol may be used in these patients (Holick 2011).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Documentation of allergenic cross-reactivity for vitamin D analogues is limited. However, because of similarities in chemical structure and/or pharmacologic actions, the possibility of cross-sensitivity cannot be ruled out with certainty.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F166098\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hyperphosphatemia: Normal serum phosphorous concentrations  must be maintained in patients treated for hyperphosphatemia to prevent metastatic calcification.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hypoparathyroidism: Concomitant treatment with intravenous calcium, parathyroid hormone, and/or dihydrotachysterol may also be required when treating hypoparathyroidism.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Obesity: Adults with a BMI &gt;30 kg/m<sup>2</sup> are at high risk for vitamin D deficiency due to storage of vitamin D in adipose tissue.  Doses higher than the RDA may be required, but must be carefully monitored to avoid toxicity (Holick, 2011).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Renal impairment:  Metabolism of vitamin D may be altered in patients with chronic kidney disease. Supplementation with ergocalciferol may be needed; close monitoring is required (KDOQI, 2003).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Rickets: The range between therapeutic and toxic doses is narrow in vitamin D-resistant rickets; adjust dose based on clinical response to avoid toxicity. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Propylene glycol: Oral solutions may contain propylene glycol; toxicities may occur if large doses of vitamin D are required. Alternate dosage forms/products should be used (Misra, 2008).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Tartrazine: Products may contain tartrazine, which may cause allergic reactions in certain individuals. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Appropriate use: Adequate calcium supplementation is required; calcium and phosphorous levels must be monitored during therapy. All sources of vitamin D (eg, dietary supplements, fortified foods, medication) should be evaluated.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Toxicity: Effects of vitamin D can last &ge;2 months after therapy is discontinued.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299278\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F166103\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=10150&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Aluminum Hydroxide: Vitamin D Analogs may increase the serum concentration of Aluminum Hydroxide. Specifically, the absorption of aluminum may be increased, leading to increased serum aluminum concentrations. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bile Acid Sequestrants: May decrease the serum concentration of Vitamin D Analogs. More specifically, bile acid sequestrants may impair absorption of Vitamin D Analogs. Management: Avoid concomitant administration of vitamin D analogs and bile acid sequestrants (eg, cholestyramine). Separate administration of these agents by several hours to minimize the potential risk of interaction. Monitor plasma calcium concentrations.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Calcium Salts: May enhance the adverse/toxic effect of Vitamin D Analogs.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiac Glycosides: Vitamin D Analogs may enhance the arrhythmogenic effect of Cardiac Glycosides. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Danazol: May enhance the hypercalcemic effect of Vitamin D Analogs.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mineral Oil: May decrease the serum concentration of Vitamin D Analogs. More specifically, mineral oil may interfere with the absorption of Vitamin D Analogs. Management: Avoid concomitant, oral administration of mineral oil and vitamin D analogs. Consider separating the administration of these agents by several hours to minimize the risk of interaction. Monitor plasma calcium concentrations.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Fluoride (with ADE): May enhance the adverse/toxic effect of Vitamin D Analogs.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Minerals (with ADEK, Folate, Iron): May enhance the adverse/toxic effect of Vitamin D Analogs.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Orlistat: May decrease the serum concentration of Vitamin D Analogs. More specifically, orlistat may impair absorption of Vitamin D Analogs. Management: Monitor clinical response (including serum calcium) to oral vitamin D analogs closely if used with orlistat.  If this combination must be used, consider giving the vitamin D analog at least 2 hrs before or after orlistat.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sucralfate: Vitamin D Analogs may increase the serum concentration of Sucralfate. Specifically, the absorption of aluminum from sucralfate may be increased, leading to an increase in the serum aluminum concentration. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thiazide and Thiazide-Like Diuretics: May enhance the hypercalcemic effect of Vitamin D Analogs.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin D Analogs: May enhance the adverse/toxic effect of other Vitamin D Analogs.<i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F166105\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5075482\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were observed in some animal reproduction studies. The ergocalciferol (vitamin D<sub>2</sub>) metabolite, 25(OH)D, crosses the placenta; maternal serum concentrations correlate with fetal concentrations at birth (Misra, 2008; Wagner, 2008).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Vitamin D deficiency in a pregnant woman may lead to a vitamin D deficiency in the neonate (Misra, 2008; Wagner, 2008). Serum 25(OH)D concentrations should be measured in pregnant women considered to be at increased risk of deficiency (ACOG, 2011). The amount of vitamin D contained in prenatal vitamins may not be adequate to treat a deficiency during pregnancy; although larger doses may be needed, current guidelines recommend a total of 1000 to 2000 units/day until more safety data is available (ACOG, 2011; Holick, 2011). In women not at risk for deficiency, doses larger than the RDA should be avoided during pregnancy (ACOG, 2011).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5075484\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">The 25(OH)D metabolite can be detected in breast milk. The manufacturer recommends that caution be used if ergocalciferol is administered to nursing women. Hypercalcemia has been noted in a breast-feeding infant following maternal use of large amounts of vitamin D; calcium serum concentrations should be monitored in nursing infants exposed to large doses.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Small quantities of vitamin D are found in breast milk following normal maternal exposure via sunlight and diet. The amount in breast milk does not correlate with serum levels in the infant and the vitamin D content of human milk is not enough to meet the recommended intake for a nursing infant. Therefore, vitamin D supplementation is recommended in all infants who are partially or exclusively breast fed (Misra, 2008; Wagner, 2008).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5075487\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Vitamin D is found in egg yolks, fatty fish, fortified milk, fortified cereal, and infant formulas; it is also produced by exposure to sunlight (IOM 2011). Multivitamin supplements containing vitamin D may be required for breast fed infants, those ingesting &lt;1,000 ml/day of vitamin D-fortified formula or milk, adolescents who do not obtain 400 units/day through vitamin D-fortified milk (100 units/8 ounce serving), and children at increased risk of vitamin D deficiency.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Supplemental calcium and/or phosphorous may be required depending on the indication for therapy. Alternately, a low phosphate diet and/or the use of a nonaluminum-binding agent may be required.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">\n      <b>Dietary Reference Intake for Vitamin D (IOM 2011):</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants 0 to 12 months: Adequate intake: 400 units/day</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">1 to 18 years: RDA: 600 units/day</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">19 to 70 years: RDA: 600 units/day</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&gt;70 years: RDA: 800 units/day</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Pregnancy/Lactating: RDA: 600 units/day</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F166107\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Serum calcium and phosphorus at least every 2 weeks; x-ray bones monthly until stabilized; signs and symptoms of vitamin D intoxication.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Serum 25(OH)D should be monitored in patients at risk for vitamin D deficiency; Serum 1,25-dihydroxyvitamin D may be used in conditions such as acquired or inherited vitamin D disorders (eg, chronic kidney disease, vitamin D resistant rickets) or phosphate metabolism (Holick, 2011).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">When treating vitamin D deficiency in children, monitor serum calcium, phosphorus and alkaline phosphatase (ALP) one month after starting therapy; serum calcium, phosphorous, magnesium, ALP, 25(OH)D, and PTH as well as x-ray (may also consider urine calcium/creatinine ratio) after 3 months; 25(OH)D yearly (Misra, 2008).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Children at increased risk of vitamin D deficiency (chronic fat malabsorption, chronic antiseizure medication use) require serum 25(OH)D, PTH, and bone mineral status to evaluate. If vitamin D supplement required, then 25(OH)D levels should be repeated at 3-month intervals until normal. PTH and bone mineral status should be monitored every 6 months until normal. (Wagner, 2008).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Vitamin D deficiency/insufficiency in patients with CKD stages 3 to 4: Measure serum 25(OH)D levels after 3 months of treatment in children or after 6 months in adults. Measure corrected total calcium and phosphorous after 1 month and then at least every 3 months in children and at least every 3 months in  adults. Discontinue ergocalciferol (or any vitamin D supplements) if the corrected total serum calcium level is &gt;10.2 mg/dL. (K/DOQI, 2003; K/DOQI, 2005).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Serum 25(OH)D in patients on long term anticonvulsant medications, antifungals, cholestyramine, glucocorticoids, or medications to treat the human immunodeficiency virus (HIV); the catabolism of the metabolite 25(OH)D may be increased (Holick, 2011).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F166110\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Serum calcium times phosphorus should not exceed 70 mg<sup>2</sup>/dL<sup>2</sup> to avoid ectopic calcification</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin D deficiency: There is no clear consensus on a reference range for total serum 25(OH)D concentrations or the validity of this level as it relates clinically to bone health. In addition, there is significant variability in the reporting of serum 25 (OH)D levels as a result of different assay types in use. However, the following ranges have been suggested:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults (IOM, 2011):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&lt;12 ng/mL (30 nmol/L): At risk for deficiency</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">12 to 20 ng/mL (30 to 50 nmol/L): Potentially at risk for inadequacy </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&ge;20 ng/mL (50 nmol/L): Sufficient levels in practically all persons</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&gt;50 ng/mL (125 nmol/L): Concern for risk of toxicity</p>\n    <p style=\"text-indent:-4em;margin-left:6em;margin-right:4em;\">Osteoporosis patients (NOF [Cosman 2014]): ~30 ng/mL (75 nmol/L): Recommended level to reach and maintain</p>\n    <p style=\"text-indent:-4em;margin-left:6em;margin-right:4em;\">Children (Misra, 2008):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&lt;15 ng/mL (37.5 nmol/L): At risk for deficiency</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">15 to 20 ng/mL (37.5 to 50 nmol/L): Potentially at risk for inadequacy</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&ge;20 ng/mL (50 nmol/L): Sufficient levels in practically all children</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&gt;100 ng/mL (250 nmol/L): Concern for risk of toxicity</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Concentrations of 25(OH)D &gt;30 ng/mL may increase the risk of hypercalciuria and hypercalcemia  in patients with extrarenal production of 1,25-dihydroxyvitamin D (Holick 2011).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F166097\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Ergocalciferol (vitamin D<sub>2</sub>) is a provitamin. The active metabolite, 1,25-dihydroxyvitamin D (calcitriol), stimulates calcium and phosphate absorption from the small intestine, promotes secretion of calcium from bone to blood; promotes renal tubule phosphate resorption.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F166115\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: 10 to 24 hours; Maximum effect: ~1 month following daily doses</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Absorbed in the small intestine; fat soluble; requires bile (IOM, 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Inactive until hydroxylated hepatically to 25-hydroxyvitamin D [25(OH)D; calcifediol] then renally to the active metabolite 1,25-dihydroxyvitamin D (calcitriol)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life, circulating: 25(OH)D: 2 to 3 weeks; 1,25-dihydroxyvitamin D ~4 hours (Holick, 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Feces (IOM, 2011)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5686151\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Calcidol Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">8000 units/mL (60 mL): $99.78</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Calciferol Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">8000 units/mL (60 mL): $206.22</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Ergocalciferol Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">8000 units/mL (60 mL): $88.75</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F166120\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Adekon (MX);</li>\n      <li>Aderowest (MX);</li>\n      <li>AFI-D2 forte (NO);</li>\n      <li>Aquasol AD (MX);</li>\n      <li>Axed (MX);</li>\n      <li>Biocatines D2 (ES);</li>\n      <li>Calciferol (CZ);</li>\n      <li>Calciferol BD (TH);</li>\n      <li>D-forte (FI);</li>\n      <li>DePURA (BR);</li>\n      <li>Devitol (AT, FI);</li>\n      <li>Endo-D (IT);</li>\n      <li>Ergosterina Irradiata (IT);</li>\n      <li>Farmobion D2 (IT);</li>\n      <li>Infadin (CZ);</li>\n      <li>Jekovit (FI);</li>\n      <li>One-Alpha (AE, BB, BF, BH, BJ, BM, BS, BZ, CI, CY, EG, ET, GH, GM, GN, GY, IL, IQ, IR, JM, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, NE, NG, NL, OM, PR, QA, SA, SC, SD, SL, SN, SR, SY, TN, TT, TZ, UG, YE, ZA, ZM, ZW);</li>\n      <li>Ostelin (AU, IT);</li>\n      <li>Pharmaton Complex (MX);</li>\n      <li>Raquiferol (AR);</li>\n      <li>Raquiferol BC (PY);</li>\n      <li>Raquiferol D2 (PE);</li>\n      <li>Sterogyl (BE, LU);</li>\n      <li>Sterogyl-15 (FR);</li>\n      <li>Uvesterol D (FR);</li>\n      <li>Vigantol (ES);</li>\n      <li>Vigantolo (IT);</li>\n      <li>Vitamina D2 Salf (IT);</li>\n      <li>Vitaminol (GR)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    ACOG Committee on Obstetric Practice. ACOG Committee Opinion No. 495: Vitamin D: Screening and supplementation during pregnancy. <i>Obstet Gynecol</i>. 2011;118(1):197-198. doi: 10.1097/AOG.0b013e318227f06b.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vitamin-d2-ergocalciferol-drug-information/abstract-text/21691184/pubmed\" target=\"_blank\" id=\"21691184\">21691184</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cosman F, de Beur SJ, LeBoff MS, et al. Clinician's Guide to Prevention and Treatment of Osteoporosis. <i>Osteoporos Int</i>. 2014;25(10):2359-2381.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vitamin-d2-ergocalciferol-drug-information/abstract-text/25182228/pubmed\" target=\"_blank\" id=\"25182228\">25182228</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Drisdol (ergocalciferol) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis; April 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Holick MF, Binkley NC, Bischoff-Ferrari HA, et al; Endocrine Society. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline (published correction appears in <i>J Clin Endocrinol Metab</i>. 2011;96[12]:3908). <i>J Clin Endocrinol Metab</i>. 2011;96(7):1911-1930. doi: 10.1210/jc.2011-0385.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vitamin-d2-ergocalciferol-drug-information/abstract-text/21646368/pubmed\" target=\"_blank\" id=\"21646368\">21646368</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    IOM (Institute of Medicine), <i>Dietary Reference Intakes for Calcium and Vitamin D</i>, Washington, DC: The National Academies Press, 2011.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &ldquo;K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Children With Chronic Kidney Disease.&rdquo; Available at  https://www.kidney.org/sites/default/files/docs/bone_children_nkfguideline.pdf</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &ldquo;K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease. Guideline 7. Prevention and Treatment of Vitamin D Insufficiency and Vitamin D Deficiency in CKD Patients.&rdquo; Available at  http://www2.kidney.org/professionals/KDOQI/guidelines_bone/Guide7.htm</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Misra M, Pacaud D, Petryk A, et al, &quot;Vitamin D Deficiency in Children and Its Management: Review of Current Knowledge and Recommendations,&quot; <i>Pediatrics</i>, 2008, 122(2):398-417.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vitamin-d2-ergocalciferol-drug-information/abstract-text/18676559/pubmed\" target=\"_blank\" id=\"18676559\">18676559</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Myrianthopoulos M, &ldquo;Dietary Treatment of Hyperlipidemia in the Elderly,&rdquo; <i>Clin Geriatr Med</i>, 1987, 3(2):343-59.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vitamin-d2-ergocalciferol-drug-information/abstract-text/3581018/pubmed\" target=\"_blank\" id=\"3581018\">3581018</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Riggs BL and Melton LJ, &ldquo;The Prevention and Treatment of Osteoporosis,&rdquo; <i>N Engl J Med</i>, 1992, 327(9):620-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vitamin-d2-ergocalciferol-drug-information/abstract-text/1640955/pubmed\" target=\"_blank\" id=\"1640955\">1640955</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wagner CL, Greer FR, and the Section on Breastfeeding and Committee on Nutrition, &ldquo;Prevention of Rickets and Vitamin D Deficiency in Infants, Children, and Adolescents,&rdquo; <i>Pediatrics</i>, 2008, 122(5):1142-52.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vitamin-d2-ergocalciferol-drug-information/abstract-text/18977996/pubmed\" target=\"_blank\" id=\"18977996\">18977996</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 10150 Version 165.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F166127\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F166128\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F166157\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F166131\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F166147\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F15822439\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F15822440\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F166109\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F166094\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F25571070\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F166112\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25575027\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F166164\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F166101\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F166116\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F166098\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299278\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F166103\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F166105\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F5075482\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F5075484\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F5075487\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F166107\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F166110\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F166097\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F166115\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F5686151\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F166120\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/10150|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=vitamin-d2-ergocalciferol-patient-drug-information\" class=\"drug drug_patient\">Vitamin D2 (ergocalciferol): Patient drug information</a></li><li><a href=\"topic.htm?path=vitamin-d2-ergocalciferol-pediatric-drug-information\" class=\"drug drug_pediatric\">Vitamin D2 (ergocalciferol): Pediatric drug information</a></li></ul></div></div>","javascript":null}